Sonnet BioTherapeutics, Sarcoma Oncology Center Collaborating to Advance Pancreatic Cancer Drug Trial

MT Newswires Live08-20

Sonnet BioTherapeutics (SONN) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.

Financial details weren't disclosed.

Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.

Sonnet shares were nearly 3% higher in recent trading.

Price: 0.70, Change: +0.03, Percent Change: +5.16

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2460548120?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-08-20 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2460548120","market":"us","top_or_hot":-1,"title":"Sonnet BioTherapeutics, Sarcoma Oncology Center Collaborating to Advance Pancreatic Cancer Drug Trial","media":"MT Newswires Live","content":"<html><body><p> Sonnet BioTherapeutics (SONN) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.</p><p>Financial details weren't disclosed.</p><p>Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.</p><p>Sonnet shares were nearly 3% higher in recent trading.</p><p>Price: 0.70, Change: +0.03, Percent Change: +5.16</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sonnet BioTherapeutics, Sarcoma Oncology Center Collaborating to Advance Pancreatic Cancer Drug Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSonnet BioTherapeutics, Sarcoma Oncology Center Collaborating to Advance Pancreatic Cancer Drug Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-20 00:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sonnet BioTherapeutics (SONN) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SONN","symbol_name":"Sonnet BioTherapeutics Holdings, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2460548120","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460548120","pubTimestamp":1724086124,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sonnet BioTherapeutics  said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.Financial details weren't disclosed.Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.Sonnet shares were nearly 3% higher in recent trading.Price: 0.70, Change: +0.03, Percent Change: +5.16","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"SONN":"Sonnet BioTherapeutics Holdings, Inc."},"translate_title":"Sonnet BioTherapeutics与肉瘤肿瘤中心合作推进胰腺癌药物试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SONN":0.9},"content_text":"Sonnet BioTherapeutics (SONN) said Monday it is collaborating with Sarcoma Oncology Center to advance the development of SON-1210, the company's proprietary bifunctional treatment combining human Interleukins IL-12 and IL-15, with chemotherapy for metastatic pancreatic cancer.Financial details weren't disclosed.Under the collaboration, SON-1210 is expected to enter a phase 1/2a clinical trial to evaluate its effectiveness with existing chemotherapy agents for metastatic pancreatic cancer, the company said, adding that it will supply the drug and support services for the trial.Sonnet shares were nearly 3% higher in recent trading.Price: 0.70, Change: +0.03, Percent Change: +5.16","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460548120"}